Related Experiment Videos

Inhibition of oral carcinogenesis by a protease inhibitor

Insights

Bowman-Birk inhibitor (BBI) significantly reduced oral tumors induced by 7,12-dimethylbenz[a]anthracene (DMBA) in hamsters. BBI also decreased elevated protease activity linked to DMBA carcinogenesis, unlike SBTI or inactivated BBI.

Area of Science:

  • Biochemistry
  • Oncology
  • Protease Inhibitors

Background:

  • 7,12-dimethylbenz[a]anthracene (DMBA) is a potent carcinogen used to induce oral tumors in experimental models.
  • Protease activity is implicated in cancer progression and metastasis.

Purpose of the Study:

  • To investigate the chemopreventive effects of Bowman-Birk inhibitor (BBI) and soybean trypsin inhibitor (SBTI) on DMBA-induced oral carcinogenesis.
  • To assess the impact of these inhibitors on associated protease activity.

Main Methods:

  • Syrian male hamsters were treated topically with DMBA, BBI, SBTI, or autoclaved BBI on cheek pouches for 20 weeks.
  • Tumor incidence, number, and mass were evaluated grossly and microscopically.
  • Protease activity using Boc-Val-Pro-Arg-MCA substrate was measured in cheek pouch tissues.

Main Results:

  • BBI significantly reduced the number of invasive carcinomas, total tumors, and tumor mass compared to DMBA alone.
  • Protease activity was elevated in DMBA-treated tissues and significantly decreased by BBI treatment.
  • SBTI and autoclaved BBI did not show significant reduction in tumors or protease activity.

Conclusions:

  • Bowman-Birk inhibitor demonstrates chemopreventive efficacy against DMBA-induced oral carcinogenesis.
  • The reduction in protease activity by BBI suggests its role in the mechanism of chemoprevention.
  • This protease activity, potentially a serine protease, may be a key factor in DMBA-induced oral cancer development.

Related Concept Videos